Depression drugs can be difficult to come off due to withdrawal symptoms. Gradual tapering with tapering support is needed to help patients withdraw safely.
OBJECTIVE:
To review the withdrawal success rates, using any intervention, and the effects on relapse/recurrence rates, symptom severity, quality of life, and withdrawal symptoms.
METHODS:
Systematic review based on PubMed and Embase searches (last search 4 October 2022) of randomised trials with one or more treatment arms aimed at helping patients withdraw from a depression drug, regardless of indication for treatment. We calculated the mean and median success rates and the risk difference of depressive relapse when discontinuing or continuing depression drugs.
RESULTS:
We included 13 studies (2085 participants). Three compared two withdrawal interventions and ten compared drug discontinuation vs. continuation. The success rates varied hugely between the trials (9% to 80%), with a weighted mean of 47% (95% confidence interval 38% to 57%) and a median of 50% (interquartile range 29% to 65%). A meta-regression showed that the length of taper was highly predictive for the risk of relapse (P = 0.00001). All the studies we reviewed confounded withdrawal symptoms with relapse; did not use hyperbolic tapering; withdrew the depression drug too fast; and stopped it entirely when receptor occupancy was still high.
CONCLUSION:
The true proportion of patients on depression drugs who can stop safely without relapse is likely considerably higher than the 50% we found.
LernerAKleinM. Dependence, withdrawal and rebound of CNS drugs: An update and regulatory considerations for new drugs development. Brain Commun. 2019;1:fcz025.
2.
BaldessariniRJTondoL. Effects of treatment discontinuation in clinical psychopharmacology. Psychother Psychosom. 2019;88:65–70.
3.
DaviesJReadJ. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?Addict Behav. 2019;97:111–21.
4.
OstrowLJessellLHurdMDiscontinuing psychiatric medications: A survey of long-term users. Psychiatr Serv. 2017;68:1232–8.
5.
NielsenMHansenEHGøtzschePC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012;107:900–8.
6.
FavaGAGattiABelaiseCWithdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom. 2015;84:72–81.
7.
GøtzschePC. Mental Health Survival Kit and Withdrawal from Psychiatric Drugs. Ann Arbor: L H Press; 2022.
8.
van GeffenECGHugtenburgJGHeerdinkERDiscontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: Tapering versus abrupt discontinuation. Eur J Clin Pharmacol. 2005;61:303–7.
9.
MurataYKobayashiDImutaNEffects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010;30:11–7.
10.
HimeiAOkamuraT. Discontinuation syndrome associated with paroxetine in depressed patients: A retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs. 2006;20:665–72.
11.
HorowitzMATaylorD. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:538–46.
12.
CosciFChouinardG. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89:283–306.
13.
MeyerJHWilsonAASagratiSSerotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826–35.
14.
ArakawaRTatenoAKimWTime-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB. Psychiatry Res Neuroimaging. 2016;251:1–6.
15.
TakanoA.SuzukiK.KosakaJ.A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology. 2006;185:395–9.
16.
ArebergJLuntang-JensenMSøgaardBOccupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012;10:401–4.
17.
SørensenARuhéHGMunkholmK. The relationship between dose and serotonin transporter occupancy of antidepressants – a systematic review. Mol Psychiatry. 2022;27:192–201.
18.
RuheHGHorikxAvan AvendonkMJPTapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:561–2.
19.
BosmanRCHuijbregtsKMVerhaakPFLong-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care. Br J Gen Pract. 2016;66:e708-19.
20.
LeydonGMRodgersLKendrickT. A qualitative study of patient views on discontinuing long-term selective serotonin reuptake inhibitors. Fam Pract. 2007;24:570–5.
21.
Verbeek-HeidaPMMathotEF. Better safe than sorry-why patients prefer to stop using selective serotonin reuptake inhibitor (SSRI) antidepressants but are afraid to do so: Results of a qualitative study. Chronic Illn. 2006;2:133–42.
22.
EveleighRSpeckensAvan WeelCPatients’ attitudes to discontinuing not-indicated long-term antidepressant use: barriers and facilitators. Ther Adv Psychopharmacol. 2019;9:2045125319872344.
23.
MaundEDewar-HaggartRWilliamsSBarriers and facilitators to discontinuing antidepressant use: A systematic review and thematic synthesis. J Affect Disord. 2019;245:38–62.
24.
HuijbersMJWentinkCSimonsEDiscontinuing antidepressant medication after mindfulness-based cognitive therapy: a mixed-methods study exploring predictors and outcomes of different discontinuation trajectories, and its facilitators and barriers. BMJ Open. 2020;10:e039053.
GøtzschePC. Farlige råd om for hurtig udtrapning af antidepressiva. Ugeskr Læger. 2021;183:464.
28.
MoherDLiberatiATetzlaffJPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097.
29.
UlfvarsonJAdamiJWredlingRControlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression. Eur J Clin Pharmacol. 2003;59:735–40.
30.
FavaGARuiniCRafanelliCSix-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry. 2004;161:1872–6.
31.
FavaGARafanelliCGrandiSSix-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1998;155:1443–5.
32.
ScholtenWDBatelaanNMvan OppenPThe efficacy of a group CBT relapse prevention program for remitted anxiety disorder patients who discontinue antidepressant medication: A randomized controlled trial. Psychother Psychosom. 2018;87:240–2.
33.
KuykenWHayesRBarrettBThe effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: Results of a randomised controlled trial (the PREVENT study). Health Technol Assess. 2015;19:1–124.
34.
KuykenWByfordSTaylorRSMindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol. 2008;76:966–78.
35.
HuijbersMJSpinhovenPSpijkerJDiscontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. Br J Psychiatry. 2016;208:366–73.
36.
BocktingCLHKleinNSElgersmaHJEffectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): A three-group, multicentre, randomised controlled trial. Lancet Psychiatry. 2018;5:401–10.
37.
SchmidtNBWollaway-BickelKTrakowskiJHAntidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behav Res Ther. 2002;40:67–73.
38.
CookBLHelmsPMSmithREUnipolar depression in the elderly. Reoccurrence on discontinuation of tricyclic antidepressants. J Affect Disord. 1986;10:91–4.
39.
BerghSSelbækGEngedalK. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): Double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012;344:e1566.
40.
EveleighRMuskensELucassenPWithdrawal of unnecessary antidepressant medication: a randomised controlled trial in primary care. BJGP Open. 2018;1:bjgpopen17X101265.
41.
KleinNSvan RijsbergenGDTen DoesschateMCBeliefs about the causes of depression and recovery and their impact on adherence, dosage, and successful tapering of antidepressants. Depress Anxiety. 2017;34:227–35.
42.
FavaGABernardiMTombaEEffects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007;10:835–8.
43.
FlintAJRifatSL. Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry. 1999;156:943–5.
44.
BerghSEngedalK. The withdrawal of antipsychotics and antidepressants from patients with dementia and BPSD living in nursing homes: An open pilot study. Int J Geriatr Psychiatry. 2008;23:877–9.
45.
JohnsonCFMacdonaldHJAtkinsonPReviewing long-term antidepressants can reduce drug burden: A prospective observational cohort study. Br J Gen Pract. 2012;62:e773-9.
46.
PsarosCFreemanMSafrenSADiscontinuation of antidepressants during attempts to conceive: A pilot trial of cognitive behavioral therapy for the prevention of recurrent depression. J Clin Psychopharmacol. 2014;34:455–60.
47.
BowersMBMcKayBGMazureCM. Discontinuation of antidepressants in newly admitted psychotic patients. J Neuropsychiatry Clin Neurosci. 2003;15:227–30.
48.
PadalaPRPadalaKPMongaVReversal of SSRI-associated apathy syndrome by discontinuation of therapy. Ann Pharmacother. 2012;46:e8.
49.
CromartyPJonssonJMoorheadSCognitive behaviour therapy for withdrawal from antidepressant medication: a single case series. Behav Cogn Psychother. 2011;39:77–97.
50.
DamlujiNFFergusonJM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol. 1988;8:347–9.
51.
DevanandDPKimMKNoblerMS. Fluoxetine discontinuation in elderly dysthymic patients. Am J Geriatr Psychiatry. 1997;5:83–7.
52.
MarkowitzJS. Selective serotonin reuptake inhibitor discontinuation with ECT and withdrawal symptoms. J ECT. 1998;14:55.
53.
FavaGABelaiseC. Discontinuing antidepressant drugs: Lesson from a failed trial and extensive clinical experience. Psychother Psychosom. 2018;87:257–67.
54.
AryaDK. Withdrawal after discontinuation of paroxetine. Aust N Z J Psychiatry. 1996;30:702.
55.
PhelpsJ. Tapering antidepressants: is 3 months slow enough?Med Hypotheses. 2011;77:1006–8.
56.
ScholtenWDBatelaanNMvan OppenPDiscontinuation of antidepressants in remitted anxiety disorder patients: the need for strategies to prevent relapse. Psychother Psychosom. 2013;82:399–400.
57.
JackimLW. The medication solution: tapering down. Behav Healthc Tomorrow. 2004;13:15–9.
58.
PiesRW. Antidepressant discontinuation: A tale of two narratives. J Clin Psychopharmacol. 2019;39:185–8.
59.
FavaGAGrandiSZieleznyMCognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry. 1994;151:1295–9.
60.
BaldessariniRJTondoLGhianiCIllness risk following rapid versus gradual discon-tinuation of antidepressants. Am J Psychiatry. 2010;167:934–41.
61.
PhelpsJManipodV. Treating anxiety by discontinuing antidepressants: A case series. Med Hypotheses. 2012;79:338–41.
62.
SegalZVBielingPYoungTAntidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry. 2010;67:1256–64.
63.
TintAHaddadPMAndersonIM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: A randomised study. J Psychopharmacol. 2008;22:330–2.
64.
KhanAMusgnungJRameyTAbrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol. 2014;34:365–8.
65.
FeducciaAAJeromeLMithoeferMCDiscontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology. 2021;238:581–8.
66.
MolenaarNMBrouwerMEBurgerHPreventive cognitive therapy with antidepressant discontinuation during pregnancy: Results from a randomized controlled trial. J Clin Psychiatry. 2020;81:19l13099 67.
67.
LewisGMarstonLDuffyLMaintenance or discontinuation of antidepressants in primary care. N Engl J Med. 2021;385:1257–67.
68.
DuffyLClarkeCSLewisGAntidepressant medication to prevent depression relapse in primary care: The ANTLER RCT. Health Technol Assess. 2021;25:1–62.
69.
ClarkeCSDuffyLLewisGCost-utility analysis of discontinuing antidepressants in England. Primary care patients compared with long-term maintenance: The ANTLER study. Appl Health Econ Health Policy. 2022;20:269–82.
70.
GeddesJRCarneySMDaviesCRelapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet. 2003;361:653–61.
71.
GluePDonovanMRKolluriSMeta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry. 2010;44:697–705.
72.
HorowitzM. Response to: Half of people who stopped long term antidepressants relapsed within a year, study finds. BMJ. 2021;374:n2403.
73.
GrootPCvan OsJ. Antidepressant tapering strips to help people come off medication more safely. Psychosis. 2018;10:142–5.
74.
MaundEStuartBMooreMManaging antidepressant discontinuation: A systematic review. Ann Fam Med. 2019;17:52–60.
75.
BreedveltJJFWarrenFCSegalZContinuation of antidepressants vs sequential psychological interventions to prevent relapse in depression: An individual participant data meta-analysis. JAMA Psychiatry. 2021;78:868–75.
76.
Van LeeuwenEvan DrielMLHorowitzMAApproaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev. 2021;4:CD013495.
GøtzschePC. Deadly Psychiatry and Organised Denial. Copenhagen: People’s Press; 2015.
79.
MoncrieffJCooperREStockmannTThe serotonin theory of depression: A systematic umbrella review of the evidence. Mol Psychiatry. 2023;28:3243–56. doi:10.1038/s41380-022-01661-0.
80.
CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet. 2018;391:1357–66.
MunkholmKPaludan-MüllerASBoesenK. Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis. BMJ Open. 2019;9:e024886.
83.
GøtzschePC. Long-term use of antipsychotics and antidepressants is not evidence-based. Int J Risk Saf Med. 2020;31(1):37–42. doi:10.3233/JRS-195060.
84.
HorowitzMAFramerAHengartnerMPEstimating risk of antidepressant withdrawal from a review of published data. CNS Drugs. 2023;37:143–57.
